Max Robotics — Global Service Robot Directory + US Certification

About

Heinrich Seegenschmiedt is a leading figure in radiation oncology, with a particular focus on stereotactic body radiotherapy (SBRT) and the management of benign and malignant tumors. His major contributions lie in advancing the precision and standardization of SBRT, especially for early-stage non-small cell lung cancer (NSCLC). His highly cited 2017 planning benchmark study, which has garnered over 50 citations, established critical guidelines for treatment planning and quality assurance, directly improving clinical outcomes and reproducibility across institutions. Beyond lung cancer, Seegenschmiedt has been instrumental in exploring SBRT for oligometastatic disease and benign conditions like arteriovenous malformations, demonstrating the technique's versatility. His work has shaped international consensus protocols and influenced how radiation is delivered with high accuracy and minimal toxicity. With a career spanning decades, he has authored numerous influential papers and contributed to textbook chapters, earning recognition as a pioneer in hypofractionated radiotherapy. His research continues to bridge the gap between technological innovation and practical clinical application, making him a key resource for students and clinicians seeking to understand the evolution of modern radiation oncology.